Table 3.
Beta Coefficient* |
Lower 95% CI |
Upper 95% CI |
|
---|---|---|---|
CG versus control group |
0.67 | 0.10 | 1.22 |
Age (in years) | −0.02 | −0.06 | 0.03 |
Male versus female | 0.53 | −0.03 | 1.09 |
Co-morbidity (Charlson Comorbidity Index Score52, points ranging from 2 to 12) |
−0.03 | −0.19 | 0.13 |
ISS (range 1–41 points) | 0.02 | −0.03 | 0.06 |
Length of Stay (in days, ranging from 1 to 61) |
−0.08 | −0.12 | −0.04 |
Any surgery versus no surgery |
0.49 | −0.22 | 1.20 |
Any complication versus no complication |
0.51 | −0.31 | 1.32 |
White versus non-white | 0.88 | 0.07 | 1.70 |
Pre-injury ADL count (Range 0 to 5 ADL abilities, where higher= better baseline function) |
−0.47 | −0.89 | −0.05 |
Discharge to post-acute rehabilitation |
.05 | −.69 | .80 |
GC=geriatric consult; ISS=injury severity score; ADL=activity of daily living
The effect of each variable is expressed as a change in count of ADL abilities at 1 year compared to baseline. A positive effect (whose 95% confidence intervals do not cross zero) indicates that each increase in the variable is associated with functional recovery; a negative effect indicates association with decline.